罗沙司他联合促红细胞生成素治疗血液透析促红细胞生成素低反应性贫血患者1例

Roxadustat Combined with Erythropoietin in the Treatment of Hemodialysis Erythropoietin Hyporeactive Anemia: A Case Report

肾性贫血是肾衰竭患者最常见的并发症之一,本文报告了1例维持性血液透析患者治疗18个月后发生促红细胞生成素低反应性贫血,予以促红细胞生成素加量或换用低氧诱导因子脯氨酰羟化酶抑制剂(罗沙司他)治疗均不能纠正,在联合使用促红细胞生成素和罗沙司他治疗后患者的贫血情况得到了显著改善。

Renal anemia is a common complication in patients with renal failure. In this paper, we report a case of erythropoietin hyporesponsive anemia in a maintenance hemodialysis patient after 18 months of treatment, which was not corrected by erythropoietin dosing or by switching to hypoxiainducing factor prolyl hydroxylase inhibitor (Roxadustat) therapy. The patient’s anemia improved significantly after combined treatment with erythropoietin and Roxadustat.